Antigon | About us
page-template,page-template-full_width,page-template-full_width-php,page,page-id-9,ajax_updown,page_not_loaded,,vertical_menu_enabled, vertical_menu_transparency vertical_menu_transparency_on,qode-title-hidden,paspartu_enabled,paspartu_on_top_fixed,paspartu_on_bottom_fixed,vertical_menu_inside_paspartu,side_area_uncovered_from_content,footer_responsive_adv,transparent_content,qode-child-theme-ver-1.0.0,qode-theme-ver-10.0,wpb-js-composer js-comp-ver-4.12,vc_responsive

Antigon is a spinoff from ULB, which aims to improve blood safety transfusion by developing and launching at the global level, a new, Point of Care Testing device easy to use, allowing caregivers to perform a crossmatching, at the bedside, of ABO groups of the patient and transfusion bag with full reliability.

In hospitals, a blood bag could be wrongly allocated or incompatible with a patient’s blood type (errors occur in 1 out of 100,000 cases). The ABO incompatibility can lead to an intravascular hemolysis and in some cases in patient death.

Fully manual ABO cards currently available on the market require some mastery in handling and than must be correctly interpreted. Trainings of transfuser staff are very cumbersome to implement. Similarly, the alternative adopted by growing number of institutions, consisting of a single electronic administrative verification of the identity of the patient and of the blood bag will not help to fully eliminate remaining errors in patient bracelet identification.

To date, there is no complete and fully automated solution to solve this unmet need effectively.

The new Antigon device is based on a patented technology developed by Professor Francis Corazza, Head of Translational Research Laboratory ULB and Professor Hanane El Kenz, Head of the blood Bank of the University Hospital Brugmann (Brussels). A prototype has validated the complete reliability (100%) of the Antigon technology versus commercial lab automates

The new unique Antigon system will offer a double instant verification, firstly an electronic administrative validation via barcode reader and a connection to the blood bank server, and secondly the ultimate control, at the bedside, of ABO groups of both patient and transfusion bag.

This will allow to block ABO incompatibilities up to 99.65% at the time of transfusion.

Globally, 81 millions Red Blood Cell Concentrates are produced, distributed and transfused each year.  The target market is important and the strategy developed by the company Antigon will allow to reach a significant share of this new European market estimated at over €100mil consumables annually (excluding reusable instruments).  At commercial level, several global leading companies have already expressed an interest in Antigon technology.

Antigon has to set up a consortium of private development firms closely with a Technical Research Centre and the laboratories of the ULB translational research and Microfluidics ULB department to finalize the product development.

Antigon startup has completed the fundraising with private and public investors and has been created in July 2016.